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COVID-19 has resulted in the deaths of over six million people worldwide.1 In
severe cases of COVID-19, there is a pronounced decrease in the production of
interferon-β (IFN-β). INF-β, in the presence of a viral pathogen, elicits the
formation of the interferon-stimulated gene factor 3 (ISGF3), which is composed of
a phosphorylated signal transducer and activator of transcription 1 and 2 and
interferon regulatory factor 9 (STAT1, STAT2, and IRF9).4 ISGF3 is required to
activate the transcription of genes that form the body’s innate antiviral immune
response.2 To date, our lab has identified two compounds, namely KH01 and KH02
that enhance ISGF3 formation and activation in mammalian cells through binding
IRF9. This study aims to develop a model for SARS-CoV-2 infection by
specifically using A549 airway epithelial cells. If KH compounds can enhance
ISGF3 activity in these cells, then IRF9 may be a viable drug target for severe
COVID-19.
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Figure 1. COVID-19 related deaths as of March 21,
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Figure 4. KH Compounds stabilize
ISGF3. HeLa cells were treated with
the indicated concentrations of IFN-β
and KH02. Twenty-four hours later,
cells were lysed and subjected to
immunoprecipitation using an IRF9
antibody.
The
Western
blots
demonstrate more STAT1, STAT2, and
IRF9 in the presence of KH
compounds.
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Figure 6. A549 cells secrete similar amounts of IFN-β when compared to HeLa
cells. Expression of an alkaline phosphatase (SEAP) from reporter cells was used as an
indirect measure of IFN-β production in A549 and HeLa cells. Both cell lines secreted
more IFN-β as the concentration of poly I:C increased.

Conclusions
Preliminary results suggest that A549 cells exhibit a dose-dependent increase in IFN-β
production in response to poly I:C, making them both viable and more physiologically
relevant for studying the effects of SARS-CoV-2 infection.
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Figure 5. Addition of KH compounds shows significant increases in nuclear levels
of STAT-1. Cytoplasmic-Nuclear fractionation was performed on 293T cells. The
results of the fractionation were analyzed via a Western Blot. The results showed a clear
increase in the nuclear STAT-1 level in cells treated with KH compounds.
Figure 2. Type-I Interferons and the JAK-STAT signaling pathway. IFN-β binds
IFNAR1 and IFNAR2, inducing phosphorylation of STAT1 and STAT2, and the
subsequent heterodimerization with IRF9 to form ISGF3. ISGF3 is transported into the
nucleus and binds to ISREs to initiate transcription of antiviral genes, including Type I
IFN. Patients with severe cases of COVID-19 show suppression of this pathway,
disrupting the innate immune system response within infected cells. KH compounds
enhance ISGF3 activity through its putative binding partner, IRF9, and thus could serve
to combat antiviral immunosuppression by COVID-19.

Use the observed increase in JAK/STAT signaling in HEK 293 and HeLa cells as
the basis for studying A549 cells as a more physiologically relevant model for
COVID-19
Compare the ability of A549 cells to mount an antiviral response to that seen in
established HeLa cells
Increase IFN-β production in A549 cells via the stabilization of ISGF3 through the
binding of KHO2 to its putative target, IRF9

Figure 3. Increase in pSTAT1 in the presence of KH compounds. HeLa cells were
treated with IFN-β and KH02. Twenty-four hours later, cells were lysed, and proteins
were separated on a 10% SDS-PAGE gel. Immunoblotting was performed using a
pSTAT1 Y701 antibody. GAPDH served as a loading control.
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Hypothesis
A549 cells are a commercially available transformed airway epithelial cell line. If
A549 cells can serve as a model for SARS-CoV2 infection, then Poly I:C (a synthetic
RNA virus mimic) will induce ISGF3 activity in a dose-dependent manner.

Future Research
Future research will focus on studying IFN-β production in A549 cells treated with
antiviral-stimulating KH compounds. If KH compounds work in these cells, they may
serve as drug candidates for severe COVID-19.
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